CTOs on the Move

Allarity Therapeutics

www.allarity.com

 
Allarity Therapeutics (Nasdaq: ALLR) is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Cambridge, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.allarity.com
  • 210 Broadway # 201
    Cambridge, MA USA 02139
  • Phone: 401.426.4664

Executives

Name Title Contact Details

Similar Companies

Cerevance

Cerevance is advancing a promising pipeline of new treatments for central nervous system diseases.

Acro Pharmaceutical Services

Acro Pharmaceutical Services is a Sharon Hill, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Americare Medical Supply

At Americare Medical Supply, we are committed to the excellence in terms of our Quality Products, Standards of Service, and Pricing. Client satisfaction is our number one priority and we take pride in providing quality products that make a difference i...

Proneuron Biotechnologies

Proneuron Biotechnologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.